

# Inactivated SARS-CoV-2 vaccine VLA 2001 Project

11<sup>th</sup> of August, 2020


CONFIDENTIAL



## VLA2001 – SARS-CoV-2 inactivated vaccine

### Roadmap towards End 2021

 Key Milestone

 Key Milestone achieved


\* Pending regulatory approval

Inactivated SARS-CoV-2 vaccine


CONFIDENTIAL

11th of August 2020

2

## VLA2001 – SARS-CoV-2 inactivated vaccine


### Supply planning



(10)(1c)

## VLA2001 – SARS-CoV-2 inactivated vaccine

Example of investments required to supply ~ (10)(1c)  
over 2021-2022



## VLA2001 – SARS-CoV-2 inactivated vaccine

### Cost structure



| CAPEX                                                                                                                                                                                                                                                                                                    | Pre-clinical                                                                                                                                                            |
|----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|-------------------------------------------------------------------------------------------------------------------------------------------------------------------------|
| (10)(1e)                                                                                                                                                                                                                                                                                                 | <ul style="list-style-type: none"><li>+ Pre-clinical<ul style="list-style-type: none"><li>› Studies in mice</li><li>› Studies in Non-Human Primates</li></ul></li></ul> |
| Commercial operations                                                                                                                                                                                                                                                                                    | Clinical development                                                                                                                                                    |
| <ul style="list-style-type: none"><li>+ Fixed costs<ul style="list-style-type: none"><li>› Employees</li><li>› Depreciations &amp; amortization</li></ul></li><li>+ Variable costs<ul style="list-style-type: none"><li>› Bill of Materials (BOM)</li><li>› Testing</li><li>› Energy</li></ul></li></ul> | (10)(1c)                                                                                                                                                                |

## Proposal summary



| Volumes  | Funding  | Pricing & Payments terms |
|----------|----------|--------------------------|
| (10)(1c) | (10)(1c) | (10)(1c)                 |

Thank you.

